-
Onslaught of eye medicine
Time of Update: 2022-05-01
Among the new ophthalmic drugs currently under development by the company, KH906 eye drops, a class 1 new drug, has entered Phase I clinical trials for the treatment of corneal neovascularization; KH737 eye drops, which have been approved for clinical use, are used to delay the progression of myopia in children .
-
Hengrui Medicine Nimodipine Oral Liquid is about to be approved and is expected to win the first domestic imitation
Time of Update: 2022-02-19
A few days ago, the official website of the State Food and Drug Administration showed that Jiangsu Hengrui Pharmaceutical's nimodipine oral liquid entered the administrative approval stage as a 3-type imitation, and is expected to win the first domestic imitation .
-
Live to be 130 years old
Time of Update: 2021-08-05
Using Bayesian methods to estimate probabilities, the University of Washington research team predicted the maximum age of death reported from 2020 to 2100 in all 13 countries .
-
2 billion
Time of Update: 2021-03-10
On January 18, NMPA's official website reported that Yangzijiang's propofol/long-chain fat emulsion class 4 imitation listing application was approved and evaluated as such. meters intranet data sho
-
Beda Pharmaceuticals MerTK/FLT3 Dual Target Inhibitor Siudo-Clinic Clinical For Solid Tumors
Time of Update: 2020-07-11
MRX2843 is a new, powerful, oral bioavailable small molecule inhibitor and a new chemical structure owned by Beida, Mer Tyrosine Kinase (MerTK) and FMS-like tyrosine kinase 3 (FLT3) double inhibitor
-
Gorgeous upgrade of drug intelligence policy and regulation database
Time of Update: 2015-03-31
The new version of the "database of drug and intellectual policies and regulations" is not only an important reference for all walks of life to effectively prevent risks and make correct decisions, bu
